Revises provisions relating to hemp. (BDR 56-916)
SB356 revises Nevada’s hemp laws by creating a new regulatory framework for “consumable hemp products” and placing primary oversight with the Cannabis Compliance Board. The bill defines consumable hemp products as hemp- or cannabidiol-related products intended for human consumption that meet the state hemp THC threshold, and it prohibits manufacturing, storing, distributing, advertising, marketing, selling, or offering such products if they exceed the bill’s new “limit of detection” standard for THC. It also bars sales to persons under 21, requires single-package packaging with serving-size limits, requires manufacturers to maintain certificates of analysis from cannabis independent testing laboratories, and directs the Board to adopt regulations on testing, serving sizes, marketing, advertising, investigations, and penalties.
The bill also changes how hemp is treated across several parts of Nevada law. It removes the State Department of Agriculture’s authority to set the maximum THC concentration for hemp and instead hard-codes hemp’s THC limit at 0.3 percent on a dry-weight basis using post-decarboxylation or another similarly reliable testing method. Conforming changes update definitions and cross-references in cannabis, agriculture, forfeiture, and veterinary statutes. SB356 further authorizes the Cannabis Compliance Board to seize and destroy noncompliant consumable hemp products, investigate violations, refer matters for law enforcement action, and use fines and penalties deposited into a dedicated account to enforce the new hemp-product rules.
The bill’s overall sentiment appears regulatory and protective rather than permissive, with an emphasis on consumer safety, youth access restrictions, product testing, and clearer enforcement authority. Even without recorded committee testimony or votes in the provided materials, the structure of the bill suggests support for tighter oversight of intoxicating or potentially mislabeled hemp-derived products and for aligning hemp enforcement more closely with the cannabis regulatory system.
The main points of contention likely center on the shift of authority from the Department of Agriculture to the Cannabis Compliance Board, the new THC “limit of detection” standard, and the extent to which hemp-derived products should be treated like cannabis products. Businesses that manufacture or sell hemp-derived consumables may view the bill as imposing new compliance costs, testing obligations, packaging limits, and advertising restrictions. By contrast, regulators and public-safety advocates would likely support the bill’s tighter controls, age restrictions, and enforcement tools as necessary to address product safety and prevent circumvention of cannabis rules.
SB356 would substantially amend Nevada’s hemp and cannabis statutes by creating a new enforcement and regulatory regime for consumable hemp products, expanding the Cannabis Compliance Board’s powers, and narrowing the role of the Department of Agriculture in hemp THC regulation. It would affect hemp manufacturers, retailers, cannabis establishments that sell hemp-derived products, testing laboratories, and enforcement agencies, while also changing related definitions and cross-references in state law governing marijuana, hemp, forfeiture, and veterinary use.
The bill’s apparent sentiment is generally favorable toward stronger regulation and consumer protection, with a clear focus on controlling intoxicating hemp products and preventing youth access. The bill text reflects a policy choice to bring hemp-derived consumables under more direct cannabis-style oversight, suggesting support from lawmakers concerned about safety, labeling, and enforcement. No committee transcript or vote record was provided, so there is no documented opposition or recorded floor sentiment in the supplied materials.
Likely areas of contention include whether consumable hemp products should be regulated by the Cannabis Compliance Board rather than the Department of Agriculture, whether the bill’s THC standard is too strict or difficult to measure in practice, and whether the new packaging, testing, and advertising rules are burdensome for hemp businesses. Another likely dispute is the bill’s treatment of hemp-derived products sold by cannabis establishments versus other retailers, since the bill creates separate compliance pathways and expressly excludes cannabis establishments from some Department of Health and Human Services hemp-product rules. Industry stakeholders may also object to the seizure, forfeiture, and penalty provisions, while regulators and public-health advocates are likely to support them.